Price still isn’t right for Biogen’s blockbuster drug

Price still isn’t right for Biogen’s blockbuster drug
Michel Vounatsos, CEO, Biogen n Vounatsos was paid $13.6 million in pay, shares and other compensation in 2017

HSE says Spinraza drug for SMA sufferers would cost €38 million over five years, as pharma giant clocks up global annual sales of $1.72 billion

Biogen’s Spinraza clocked up global sales of $1.72 billion for the company last year.

It is being reimbursed by numerous health systems across Europe - but to varying degrees.

The HSE told Biogen that it would not reimburse Spinraza at the price it was offering.

Subscribe from just 1€

Exclusive offers

Choose the subscription that is right for you

Monthly Subscription

€1

For the first month

€19.99 Monthly Thereafter

Subscribe today

Cancel anytime

Annual Subscription

€200€149

For the first year

€199.99 annually thereafter

Subscribe today

Cancel anytime

Quarterly Subscription

€55€42

For the first 90 days

€55.00 quarterly Thereafter

Subscribe today

Cancel anytime

These offers are not available for current subscribers. Offers and pricing are subject to change without notice.

Terms & Conditions Apply

Please Subscribe or Log in to continue

Subscribe Login

Related Articles

More from The Business Post